ICER criticizes cost of 8 targeted immune modulators for UC, recommending some deep discounts
While 8 targeted immune modulators (TIMs) on the market for ulcerative colitis have proved beneficial to patients, nonprofit cost-effectiveness watchdog ICER called the drugs unreasonably expensive, recommending some deep discounts to match the drugs with their actual value.
In a report released Friday, ICER assessed the cost vs. clinical benefit of market leader Humira — for which AbbVie has faced price gouging accusations — as well as Janssen’s Simponi, Stelara and Remicade, Merck’s Renflexis, Pfizer’s Inflectra and Xeljanz, and Takeda’s Entyvio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.